ACETNasdaqPharmaceutical PreparationsFiscal year ends December 26
Adicet Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$4.53−0.04 (-0.88%)
Close on Oct 19, 2026
- Market cap
- $48.68M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
65.3%
6M of 9M shares
Institutional holders
56
14 new, 6 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
3 buys · 4 sales
Net bought $929.09K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| RA Capital Healthcare Fund, L.P. | 935,486 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Orbimed Advisors LLC | 844,787 | 8.80% | 13D (active) amendment | Apr 8, 2026 |
| Tang Capital Management, LLC | 8,223,612 | 9.90% | 13G (passive) amendment | Mar 31, 2025 |
| Franklin Advisers, Inc. | 626,571 | 6.50% | 13G (passive) | Dec 31, 2025 |
| Rajeev Shah | 1,182,624 | 12.30% | 13G (passive) amendment | Feb 17, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ACET | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 932,624 | 9.96% | $8.06M | −250,000 | 0.07% |
| Orbimed Advisors LLC | 844,787 | 9.02% | $7.30M | −183,157 | 0.14% |
| Franklin Resources Inc | 626,571 | 6.69% | $5.41M | – | 0.00% |
| Citadel Advisors LLC | 432,738 | 4.62% | $3.74M | +50,915 | 0.00% |
| Vanguard Capital Management LLC | 343,228 | 3.67% | $2.97M | +6,704 | 0.00% |
| Adage Capital Partners Gp, L.L.C. | 274,375 | 2.93% | $2.37M | – | 0.00% |
| Renaissance Technologies LLC | 265,945 | 2.84% | $2.30M | +33,354 | 0.00% |
| Stonepine Capital Management, LLC | 245,518 | 2.62% | $2.12M | +23,563 | 1.20% |
| Alyeska Investment Group, L.P. | 203,799 | 2.18% | $1.76M | – | 0.00% |
| Schonfeld Strategic Advisors LLC | 195,514 | 2.09% | $1.69M | New | 0.01% |
| Carlyle Group Inc. | 184,295 | 1.97% | $1.59M | – | 0.02% |
| NEXTBio Capital Management LP | 157,827 | 1.69% | $1.36M | – | 0.63% |
| Acadian Asset Management LLC | 124,832 | 1.33% | $1.08K | +6,694 | 0.00% |
| Two Sigma Investments, LP | 96,839 | 1.03% | $836.69K | +53,733 | 0.00% |
| Geode Capital Management, LLC | 95,634 | 1.02% | $826.70K | −5,501 | 0.00% |
| DAFNA Capital Management LLC | 93,812 | 1.00% | $810.54K | – | 0.15% |
| Bridgeway Capital Management, LLC | 85,959 | 0.92% | $742.69K | New | 0.01% |
| Marshall Wace, Llp | 79,488 | 0.85% | $686.78K | New | 0.00% |
| Trexquant Investment LP | 78,002 | 0.83% | $673.94K | +34,336 | 0.00% |
| Jane Street Group, LLC | 70,561 | 0.75% | $609.65K | +33,477 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 56 | 6M | 65.3% | 14 / 18 | 9 / 6 | 1M | 1M |
| Q1 2026 | 48 | 6M | 67.8% | 12 / 12 | 9 / 11 | 1M | 1M |
| Q4 2025 | 48 | 7M | 71.6% | 48 / 0 | 0 / 0 | 7M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ACET | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 240,946 | 2.57% | $2.08M | 0.00% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 225,186 | 2.41% | $2.05M | 0.18% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 98,912 | 1.06% | $854.60K | 0.00% | Jun 30, 2026 |
| Ultra-Small Company Fund | 85,959 | 0.92% | $742.69K | 0.75% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 47,760 | 0.51% | $444.65K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 23,940 | 0.26% | $206.84K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 17,363 | 0.19% | $161.65K | 0.00% | May 31, 2026 |
| Dimensional U.S. Small Cap ETF | 14,520 | 0.16% | $132.28K | 0.00% | Jul 31, 2026 |
| U.S. Micro Cap Portfolio | 14,264 | 0.15% | $129.95K | 0.00% | Jul 31, 2026 |
| Fidelity Series Total Market Index Fund | 12,361 | 0.13% | $115.08K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 4,839 | 0.05% | $45.05K | 0.00% | May 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 2,584 | 0.03% | $22.33K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 1,601 | 0.02% | $13.83K | 0.01% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 1,489 | 0.02% | $12.86K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 786 | 0.01% | $6.79K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Lloyd Klickstein | Chief Medical Officer, Director | 108,566 | 1.16% | Aug 7, 2026 |
| Chen Schor | President & CEO, Director | 10,159 | 0.11% | Jun 23, 2026 |
| Blake Aftab | Chief Scientific Officer | 2,981 | 0.03% | Jun 23, 2026 |
| Julia D. Maltzman | Chief Medical Officer | – | – | Mar 27, 2026 |
| Brian Nicholas Harvey | Chief Financial Officer | 5,145 | 0.05% | Mar 27, 2026 |
| Don Healey | Chief Technology Officer | 3,452 | 0.04% | Mar 27, 2026 |
| Andrew Sinclair | Director | 2,133,085 | 22.79% | Jun 23, 2026 |
| Jeffrey Chodakewitz | Director | 17,700 | 0.19% | Jun 23, 2026 |
| Michael Grissinger | Director | – | – | Jun 23, 2026 |
| Katie Peng | Director | 11,800 | 0.13% | Jun 23, 2026 |
| Steve Dubin | Director | 22,700 | 0.24% | Jun 23, 2026 |
| Ra Capital Management, L.P. | 10% owner | – | – | Apr 29, 2026 |
| Peter Kolchinsky | 10% owner | 959,028 | 10.24% | Apr 29, 2026 |
| Rajeev M. Shah | 10% owner | 932,624 | 9.96% | Apr 29, 2026 |
| Capital Healthcare Fund LP RA | 10% owner | 1,182,624 | 12.63% | Apr 29, 2026 |
| OrbiMed Israel GP II, L.P. | 10% owner | 242,285 | 2.59% | Apr 9, 2026 |
| Advisors Llc Orbimed | 10% owner | 4,490,254 | 47.97% | Apr 9, 2026 |
| Capital GP V. LLC OrbiMed | 10% owner | – | – | Apr 9, 2026 |
| Israel BioFund GP Limited Partnership OrbiMed | 10% owner | – | – | Apr 9, 2026 |
| Israel GP Ltd. OrbiMed | 10% owner | 5,243,259 | 56.01% | Apr 9, 2026 |
| Capital GP VI LLC OrbiMed | 10% owner | 292,607 | 3.13% | Apr 9, 2026 |
| Genesis GP LLC OrbiMed | 10% owner | – | – | Apr 9, 2026 |
| Advisors Israel II Ltd OrbiMed | 10% owner | 0 | – | Apr 9, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Rajeev M. Shah 10% owner | Apr 27, 2026 | Other | −250,000 | – | – | 932,624 |
| Advisors Israel II Ltd OrbiMed 10% owner | Apr 8, 2026 | Sale | −40,416 | $6.52 | $263.51K | 0 |
| Advisors Israel II Ltd OrbiMed 10% owner | Apr 8, 2026 | Sale | −32,523 | $6.29 | $204.57K | 0 |
| Advisors Israel II Ltd OrbiMed 10% owner | Apr 7, 2026 | Sale | −2,400 | $6.38 | $15.31K | 32,523 |
| Advisors Israel II Ltd OrbiMed 10% owner | Apr 7, 2026 | Sale | −29,319 | $6.53 | $191.45K | 34,923 |
| Capital Healthcare Fund LP RA 10% owner | Feb 20, 2026 | Buy | +74,751 | $7.27 | $543.44K | 1,182,624 |
| Capital Healthcare Fund LP RA 10% owner | Feb 19, 2026 | Buy | +74,268 | $7.21 | $535.47K | 1,107,873 |
| Capital Healthcare Fund LP RA 10% owner | Feb 18, 2026 | Buy | +74,577 | $7.04 | $525.02K | 1,033,605 |
| Chen Schor President & CEO, Director | Jan 24, 2026 | Tax withholding | −1,755 | $8.44 | $14.81K | 6,820 |
| Brian Nicholas Harvey Chief Financial Officer | Jan 24, 2026 | Tax withholding | −546 | $8.44 | $4.61K | 5,145 |
| Blake Aftab Chief Scientific Officer | Jan 24, 2026 | Tax withholding | −535 | $8.44 | $4.52K | 2,981 |
| Don Healey Chief Technology Officer | Jan 24, 2026 | Tax withholding | −535 | $8.44 | $4.52K | 3,452 |
| Advisors Llc Orbimed 10% owner | Oct 8, 2025 | Buy | +3,500,000 | $1.00 | $3.50M | 4,490,254 |
| Advisors Llc Orbimed 10% owner | Oct 8, 2025 | Buy | +1,500,000 | $1.00 | $1.50M | 9,026,359 |
| Jeffrey Chodakewitz Director | Jun 11, 2025 | Award | +5,900 | – | – | 17,700 |
| Andrew Sinclair Director | Jun 11, 2025 | Award | +5,900 | – | – | 17,700 |
| Katie Peng Director | Jun 11, 2025 | Award | +5,900 | – | – | 11,800 |
| Steve Dubin Director | Jun 11, 2025 | Award | +5,900 | – | – | 22,700 |
| Lloyd Klickstein Director | Jun 11, 2025 | Award | +5,900 | – | – | 108,566 |
| Don Healey Chief Technology Officer | Jan 24, 2025 | Tax withholding | −8,560 | $0.92 | $7.88K | 63,769 |
| Chen Schor President & CEO, Director | Jan 24, 2025 | Tax withholding | −28,101 | $0.92 | $25.85K | 137,201 |
| Blake Aftab Chief Scientific Officer | Jan 24, 2025 | Tax withholding | −6,270 | $0.92 | $5.77K | 56,241 |
| Brian Nicholas Harvey Chief Financial Officer | Jan 24, 2025 | Tax withholding | −8,752 | $0.92 | $8.05K | 91,048 |
| Carl L. Gordon Director, 10% owner | Jun 5, 2024 | Award | +5,900 | – | – | 11,800 |
| Steve Dubin Director | Jun 5, 2024 | Award | +5,900 | – | – | 16,800 |
| Michael Kauffman Director | Jun 5, 2024 | Award | +5,900 | – | – | 11,800 |
| Michael Kauffman Director | Jun 5, 2024 | Sale | −5,900 | $1.43 | $8.44K | 5,900 |
| Jeffrey Chodakewitz Director | Jun 5, 2024 | Award | +5,900 | – | – | 11,800 |
| Aya Jakobovits Director | Jun 5, 2024 | Award | +5,900 | – | – | 11,800 |
| Katie Peng Director | Jun 5, 2024 | Award | +5,900 | – | – | 5,900 |
| Andrew Sinclair Director | Jun 5, 2024 | Award | +5,900 | – | – | 11,800 |
| Advisors Israel II Ltd OrbiMed Director, 10% owner | Jan 25, 2024 | Buy | +1,841,100 | $2.40 | $4.42M | 7,526,359 |
| Advisors Israel II Ltd OrbiMed Director, 10% owner | Jan 25, 2024 | Buy | +1,041,700 | $2.40 | $2.50M | 1,255,985 |
| Advisors Israel II Ltd OrbiMed Director, 10% owner | Jan 25, 2024 | Buy | +242,200 | $2.40 | $581.28K | 990,254 |
| Carl L. Gordon Director, 10% owner | Jan 25, 2024 | Buy | +1,841,100 | $2.40 | $4.42M | 7,526,359 |
| Carl L. Gordon Director, 10% owner | Jan 25, 2024 | Buy | +1,041,700 | $2.40 | $2.50M | 1,255,985 |
| Carl L. Gordon Director, 10% owner | Jan 25, 2024 | Buy | +242,200 | $2.40 | $581.28K | 990,254 |
| Blake Aftab Chief Scientific Officer | Jan 24, 2024 | Tax withholding | −3,565 | $2.40 | $8.56K | 42,811 |
| Blake Aftab Chief Scientific Officer | Jan 24, 2024 | Award | +19,700 | – | – | 62,511 |
| Don Healey Chief Technology Officer | Jan 24, 2024 | Tax withholding | −4,870 | $2.40 | $11.69K | 52,629 |
| Don Healey Chief Technology Officer | Jan 24, 2024 | Award | +19,700 | – | – | 72,329 |
| Chen Schor President & CEO, Director | Jan 24, 2024 | Tax withholding | −15,290 | $2.40 | $36.70K | 138,471 |
| Chen Schor President & CEO, Director | Jan 24, 2024 | Award | +70,300 | – | – | 208,771 |
| Francesco Galimi SVP & Chief Medical Officer | Jan 24, 2024 | Tax withholding | −4,957 | $2.40 | $11.90K | 75,501 |
| Francesco Galimi SVP & Chief Medical Officer | Jan 24, 2024 | Award | +26,300 | – | – | 101,801 |
| Brian Nicholas Harvey Chief Financial Officer | Jan 24, 2024 | Tax withholding | −4,320 | $2.40 | $10.37K | 73,500 |
| Brian Nicholas Harvey Chief Financial Officer | Jan 24, 2024 | Award | +26,300 | – | – | 99,800 |
| Blake Aftab Chief Scientific Officer | Oct 12, 2023 | Tax withholding | −7,933 | $1.35 | $10.71K | 46,376 |
| Brian Nicholas Harvey Chief Financial Officer | Oct 2, 2023 | Tax withholding | −7,096 | $1.37 | $9.72K | 77,820 |
| Don Healey Chief Technology Officer | Oct 2, 2023 | Tax withholding | −9,069 | $1.37 | $12.42K | 57,499 |
| Francesco Galimi SVP & Chief Medical Officer | Oct 2, 2023 | Tax withholding | −8,093 | $1.37 | $11.09K | 80,458 |
| Chen Schor President & CEO, Director | Oct 2, 2023 | Buy | +5,500 | $1.33 | $7.32K | 43,469 |
| Chen Schor President & CEO, Director | Oct 2, 2023 | Tax withholding | −23,208 | $1.37 | $31.79K | 153,761 |
| Chen Schor President & CEO, Director | Sep 29, 2023 | Sale | −5,500 | $1.36 | $7.48K | 176,969 |
| Chen Schor President & CEO, Director | Sep 28, 2023 | Buy | +5,500 | $1.42 | $7.81K | 182,469 |
| Chen Schor President & CEO, Director | Sep 28, 2023 | Sale | −5,500 | $1.42 | $7.81K | 37,969 |
| Steve Dubin Director | Jun 30, 2023 | Buy | +5,000 | $2.40 | $12.00K | 10,900 |
| Carl L. Gordon Director, 10% owner | Jun 27, 2023 | Buy | +125,000 | $2.09 | $261.25K | 1,027,885 |
| Carl L. Gordon Director, 10% owner | Jun 27, 2023 | Buy | +250,000 | $2.09 | $522.50K | 646,657 |
| Carl L. Gordon Director, 10% owner | Jun 27, 2023 | Buy | +442,000 | $2.09 | $923.78K | 5,685,259 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| OrbiMed Genesis Master Fund, L.P. Shareholder | Apr 9, 2026 | 78,499 | $514.17K | Apr 9, 2026 | Public Offering |
| OrbiMed Israel Partners II, L.P. Shareholder | Apr 8, 2026 | 40,416 | $264.72K | Apr 8, 2026 | Merger |
| Israel Partners Limited Partnership OrbiMed Shareholder | Apr 7, 2026 | 64,242 | $413.08K | Apr 7, 2026 | Merger |
| Michael Kauffman Director | Jun 5, 2024 | 5,900 | $8.44K | Jun 5, 2024 | RESTRICTED STOCK |
| Schor Chen Officer, Director | Sep 29, 2023 | 5,500 | $7.48K | Sep 29, 2023 | Performance Stock Units |